Summary
10.87 -0.44(-3.89%)09/06/2024
Addex Therapeutics Ltd (ADXN)
Addex Therapeutics Ltd (ADXN)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-3.72 | -0.09 | 38.09 | 18.16 | 19.59 | 2,196.73 | 0.00 | -25.03 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 10.87 | |
Open | 11.31 | |
High | 11.47 | |
Low | 10.62 | |
Volume | 32,016 | |
Change | -0.42 | |
Change % | -3.72 | |
Avg Volume (20 Days) | 1,324,103 | |
Volume/Avg Volume (20 Days) Ratio | 0.02 | |
52 Week Range | 0.33 - 27.90 | |
Price vs 52 Week High | -61.04% | |
Price vs 52 Week Low | 3,194.06% | |
Range | -3.89 | |
Gap Up/Down | -0.03 |
Fundamentals | ||
Market Capitalization (Mln) | 18 | |
EBIDTA | 0 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 0.00 | |
Book Value | 2.3460 | |
Earnings Per Share | -2.6460 | |
EPS Estimate Current Quarter | 0.0000 | |
EPS Estimate Next Quarter | 0.0000 | |
EPS Estimate Current Year | 0.0000 | |
EPS Estimate Next Year | 0.0000 | |
Diluted EPS (TTM) | -2.6460 | |
Revenues | ||
Profit Marging | -2.8108 | |
Operating Marging (TTM) | -2.8240 | |
Return on asset (TTM) | -0.4347 | |
Return on equity (TTM) | -0.8976 | |
Revenue TTM | 4,643,762 | |
Revenue per share TTM | 0.8700 | |
Quarterly Revenue Growth (YOY) | 6.3820 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | -6,470,057 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 2.5405 | |
Revenue Enterprise Value | 5.2672 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 5,691,830 | |
Shares Float | 2,355,792 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 0.00 | |
Institutions (%) | 8.94 |
09/06 10:41 EST - zacks.com
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?
Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
09/04 01:00 EST - globenewswire.com
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.
08/28 11:30 EST - zacks.com
Addex Stock Soars on Crucial Update From Indivior Research Deal
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
Addex Stock Soars on Crucial Update From Indivior Research Deal
ADXN gains 55% on a crucial update from its GABAB PAM research collaboration with INDV. Both companies pick pre-clinical compounds for IND-enabling studies.
08/27 12:03 EST - benzinga.com
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
Crude Oil Dips; Addex Therapeutics Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling around 0.2% on Tuesday.
08/27 10:47 EST - invezz.com
Why Addex Therapeutics stock skyrocketed 70% on Tuesday
Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
Why Addex Therapeutics stock skyrocketed 70% on Tuesday
Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
08/27 01:00 EST - globenewswire.com
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.
07/22 01:00 EST - globenewswire.com
Addex's Partner Discontinues ADX71149 development in Epilepsy
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.
Addex's Partner Discontinues ADX71149 development in Epilepsy
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.
07/15 01:00 EST - globenewswire.com
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.
07/12 01:00 EST - globenewswire.com
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.
07/01 01:00 EST - globenewswire.com
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).
06/06 01:00 EST - globenewswire.com
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .
Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update
● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .
06/05 01:00 EST - globenewswire.com
Addex Convenes Annual General Meeting 2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
Addex Convenes Annual General Meeting 2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
05/31 01:00 EST - globenewswire.com
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
05/08 01:00 EST - globenewswire.com
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
04/29 01:00 EST - globenewswire.com
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
04/19 01:00 EST - globenewswire.com
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.
04/18 13:46 EST - seekingalpha.com
Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by.
Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by.
04/18 01:00 EST - globenewswire.com
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing cash runway beyond 2026 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 18, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
04/11 01:00 EST - globenewswire.com
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
Geneva, Switzerland, April 11, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its Full-Year 2023 Financial Results on April 18, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
04/03 01:00 EST - globenewswire.com
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, today announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
Addex receives CHF5M and 20% share of Neurosterix Perceptive Advisors leads $63M investment into Neurosterix Addex contributes portfolio of preclinical neuroscience assets and allosteric modulator small molecule discovery technology platform to Neurosterix Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, and funds affiliated with Perceptive Advisors, an investment management firm focused on the life sciences sector, today announced the launch of Neurosterix, a company focused on developing allosteric modulators for the treatment of underserved neurological disorders.